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The clinical manifestations of Myotonic Dystrophy type-1 (DM1) are associated with a 
complex mixture of multisystem features including cognitive dysfunctions that strongly 
impact on patients’ social and occupational functioning. Decision making, a function 
controlled by dopaminergic circuitry, is critical for succeeding in one’s social and 
professional life. We tested here the hypothesis that altered connectivity of the ventral 
tegmental area (VTA), one of the major sources of diffuse dopaminergic projections in 
the brain, might account for some higher-level dysfunctions observed in patients with 
DM1. In this case-control study, we recruited 31 patients with DM1 and 26 healthy 
controls who underwent the IOWA Gambling task and resting-state functional MRI 
(RS-fMRI) at 3T. Functional connectivity of the VTA was assessed using RS-fMRI. 
VTA connectivity was compared between 25 DM1 patients and all the controls, and the 
presence of associations between VTA connectivity and IOWA Gambling task 
performance was also investigated. DM1 patients performed significantly worse than 
controls at the IOWA Gambling task. A significant increase of functional connectivity 
was observed between VTA and the left supramarginal and superior temporal gyri in 
DM1 patients. Patients’ IOWA Gambling task net-scores were strictly associated with 
VTA-driven functional connectivity in the bilateral supplementary motor area and right 
precentral gyrus. This study demonstrates a prominent deficit of decision-making in 
patients with DM1. It might be related to increased connectivity between VTA and 
brain areas critically involved in the reward/punishment system and social cognition. 
These findings indicate that dopaminergic function is a potential target for 
pharmacological and non-pharmacological interventions in DM1. 
 






1. Introduction  
Myotonic dystrophy type-1 (DM1) is an autosomal dominant muscular dystrophy 
caused by a pathological CTG triplet repeat expansion in the myotonic dystrophy 
protein kinase (DMPK) gene located on chromosome 19q13 (Meola & Cardani, 2015). 
DM1 is a composite clinical condition affecting not only the skeletal muscles but also 
various organs including the brain. The neuropsychiatric manifestations of DM1 are a 
complex mixture of personality disorders and higher-level cognitive dysfunctions that 
strongly impact on patients’ social functioning (Serra et al., 2014; Serra et al., 2015; 
Serra et al., 2016a). When tested on single cognitive domains, such as memory, 
attention, language and visuo-spatial activities, DM1 patients typically perform better 
than expected (Gaul et al., 2006). In contrast, they perform poorly when assessed for 
high-order executive functions such as social cognition (Serra et al., 2016a). We have 
previously shown that failure in the daily life of DM1 patients is at least partially 
explained by theory of mind deficits, which are associated with peculiar changes of 
functional brain connectivity (Serra et al., 2016a). Nonetheless, other cognitive abilities 
are known to be implicated in the complex process of interaction with the environment, 
which adapt and modify human behaviours according to environmental modifications. 
“Decision-making” is defined as the ability to take decisions among different 
alternatives on the basis of an obtainable profit (Bechara, Damasio, Damasio & 
Anderson, 1994) The reward / punishment system is directly involved in decision-
making. Several measures can be used to assess the decision-making abilities, the Iowa 
Gambling Task (IGT) (Bechara, Damasio, Damasio & Anderson, 1994) being the most 
popular. IGT was developed to simulate real-life decisions and assess different patterns 
of decision-making between healthy subjects and patients with ventromedial prefrontal 
lesions and deficits in social functioning (Bechara, Damasio, Damasio & Anderson, 
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1994; Lin, Song, Lin & Chiu YC, 2012). Using IGT, decision-making dysfunctions 
have also been extensively demonstrated in several psychiatric (e.g., pathological 
gamblers; patients with schizophrenia) (Ciccarelli, Griffiths, Nigro & Cosenza, 2017; 
Saperia et al., 2019) and neurological disorders (i.e., patients with Parkinson’s disease 
and other neurodegenerative disorders; patients with traumatic brain injuries) 
(Gleichgerrcht, Ibáñez, Roca, Torralva & Manes, 2010; Zamarian, Weiss & Delazer M, 
2010; Yasuno et al., 2014).  
A widespread fronto-striatal cortical-subcortical circuitry is involved in the 
decision-making abilities and in the reward system (van Holst, van den Brink, Veltman, 
& Goudriaan, 2010). In fact, orbito-prefrontal and ventromedial prefrontal cortices 
together with their subcortical projections are strictly involved in these functions (van 
Holst, van den Brink, Veltman, & Goudriaan, 2010). It is well known that dopamine 
plays a prominent role in the decision-making abilities as well as in behavioural 
functions (Schaeffer & Berg et al., 2017; Chong & Husain, 2016; Kessler, Hutson, 
Herman & Potenza, 2016; Serra et al., 2018). Nevertheless, the precise cellular and 
molecular mechanisms underlying the clinical symptoms and alterations in brain 
connectivity are still far from being fully understood. Interestingly, a recent study based 
on a transgenic mouse model of DM1 highlighted a potential pathophysiological role 
for the dopamine (DA) circuitry in determining DM1 mice behavioural features 
(Ramon-Duaso et al., 2018). Significant alterations in the DA transport system, DA 
receptors, and DA levels were identified in the medial prefrontal cortex of the DM1 
animal model (Ramon-Duaso et al., 2018).  
In the DM1 animal model, the anatomical distribution of dopaminergic 
dysfunction was mainly observed in the prefrontal cortex (Ramon-Duaso et al., 2018). 
In humans, the prefrontal cortex is strongly implicated in higher-level cognitive and 
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behavioural functions as part of a more widespread network that is mainly modulated 
by subcortical dopaminergic projections (Ranganath & Jacob, 2016).  Among these, 
there is the ventral tegmental area (VTA), a brainstem structure, which is particularly 
rich in dopaminergic neurons that project diffusely to several subcortical and cortical 
areas, including the prefrontal cortex (Schultz, Dayan & Montague, 1997). This 
complex system is mainly implicated in reward mechanisms as shown in previous 
animal (Schultz, Dayan & Montague, 1997) and human studies (Krebs, Heipertz, 
Schuetze & Duzel, 2011; Richter & Gruber, 2018).  
Against this background, we hypothesise that some dopaminergic dysfunction 
might occur and play a significant role in determining some of the higher-level 
dysfunctions observed in DM1 patients. In particular, based on the results in the animal 
model (Ramon-Duaso et al., 2018) and on previous evidence of increased functional 
connectivity in DM1 patients, we anticipate that patients with DM1 might show 
increased connectivity within networks related to reward-based decision-making 
processes, which are induced by hyper-functioning VTA dopaminergic neurons.  
Resting-state functional MRI (fMRI) is a robust approach to investigate brain 
connectivity in vivo, which has recently been successfully used to investigate VTA-
driven changes in brain connectivity in humans (Serra et al., 2018). To test the 
hypothesis that VTA-driven connectivity might contribute to DM1 decision-making 
dysfunctions, we recruited a group of patients with DM1 and a group of healthy 
controls in a case-control design. They were tested with the IGT, and underwent a 
resting-state fMRI session. In DM1 patients we predicted an increased pattern of VTA-
driven connectivity in association with a decreased performance on IGT. 
 
2. Materials and Methods 
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2.1.Study design and power calculation 
This is a case-control study, with two groups: patients with DM1 and healthy controls. 
The main outcome measure is the performance at the IGT. As this is an exploratory 
study, there is no data available to compute the effect size. However, previous studies 
based on this test have shown typically large effect sizes (Bechara, Damasio, Damasio, 
Anderson, 1994; Bechara & Damasio, 2002). Therefore, a statistical power analysis was 
performed for sample size estimation for ANOVA (F test), with an alpha=.05 and 
power=0.80. The projected sample size needed with an effect size of 0.4 (GPower 3.1) 
was approximately N = 50 in total. No part of the study procedures and analyses was 
pre-registered prior to the research being conducted. 
 
2.2. Participants 
Thirty-one patients with a molecular diagnosis of DM1 were recruited from the 
Neuromuscular and Neurological Rare Diseases Centre at San Camillo Forlanini 
Hospital (Rome, Italy) and from the Institute of Neurology at the Catholic University of 
Rome (Rome, Italy) between March 2016 and December 2018. Molecular diagnosis 
was performed as described previously (IDMC, 2004). Patients were selected to have 
either an adulthood (62.5%) or a childhood-juvenile (40.1%) disease onset [mean (SD) 
CTG triplets expansion: 467 (272); mean (SD) Muscular Impairment Rating Scale 
(MIRS) (Mathieu, Boivin, Meunier, Gaudreault & Bégin, 2001) score: 2.8 (0.7)], 
whereas patients with a congenital disease onset were excluded. Twenty-six healthy 
subjects (HS), age and gender matched to the patients, were recruited through classified 
advertisements and through the dedicated mailing lists of Fondazione Santa Lucia 
(Rome, Italy), and served as controls for this study. The principal demographic and 
clinical characteristics of all participants are summarized in Table 1. All participants 
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were right handed as assessed by the Edinburgh Handedness Inventory (Büsch, 
Hagemann & Bender, 2010). A clinical assessment was run to exclude the presence of 
any pathologies different from known comorbidities in DM1 patients and major 
systemic or neurological illness in the control group. The study was approved by the 
Ethical Committee of Santa Lucia Foundation and written informed consent was 
obtained from all participants before study initiation. All procedures performed in this 
study were in accordance with the 1964 Helsinki declaration and its later amendments 
or comparable ethical standards.  
2.3.Neuropsychological assessment 
As part of the screening process, all DM1 patients were first evaluated using the 
social cognition battery (Prior, Marchi & Sartori, 2003) and the Coloured Progressive 
Raven’s Matrices (Carlesimo, Caltagirone & Gainotti, 1996). For the purpose of the 
current study, they also underwent the IGT (Bechara & Damasio, 2002) to assess risk 
preferences by simulating real-life decision-making and using uncertain rewards and 
penalties. One-hundred cards from 4 virtual decks (A, B, C, D) were presented on a 
computer screen, and participants were instructed to choose a card from one deck. They 
were told that every card would either win or lose them some game money. The goal of 
the game was to win as much money as possible. All decks contained both winning and 
losing cards, but Decks A and B were set to be disadvantageous (leading to an overall 
loss), while decks C and D were set to be advantageous (leading to an overall gain). 
Participants ignored how many cards had to be turned before the game ended. At the 
end of the game, the overall total net score [i.e., (C+D)-(A+B)] was calculated. 
Highly positive net scores indicate that advantageous decks were preferentially 
chosen in comparison to those that were disadvantageous, thus reflecting a preferential 
attitude in taking low-risk choices. Conversely, low net scores reflect the absence of a 
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preferential choice between decks, thus showing an inability to perform the necessary 
risk evaluation to get a potential reward. Finally, negative net scores indicate the 
preference to select high-risk decks (i.e. disadvantageous decks).  
Statistical analyses were performed using SPSS-21 (SPSS Inc., Chicago, 
Illinois). The performance at IGT was the primary outcome measure of the study and 
was assessed by means of deck choice using a two-way ANCOVA [Group (DM1 vs. 
HS) X Trial (Deck A vs. Deck B vs. Deck C vs. Deck D)], and by means of overall 
score by using a one-way ANOVA (Group X Net-score). Both analyses were adjusted 
for age and years of formal education.  
2.4.Image acquisition and pre-processing of resting-state fMRI 
All participants underwent an MRI scan at 3T including the following 
acquisitions: 1) T2* weighted echo planar imaging (EPI) sensitized to blood 
oxygenation level dependent (BOLD) contrast (TR=2080 ms, TE=30 ms, 32 axial slices 
parallel to AC-PC line, matrix=64x64, pixel size=3x3 mm2, slice thickness=2.5 mm, 
flip angle:70°) for resting-state fMRI; 2) a 3D Modified Driven Equilibrium Fourier 
Transform (MDEFT) scan (TR=1338 ms, TE=2.4 ms, Matrix=256x224, n. slices=176, 
thickness=1 mm) to be used as anatomical reference. BOLD EPIs were collected during 
rest for 7 min and 20 s, resulting in a total of 220 volumes. During the acquisition, 
participants were instructed to keep their eyes closed, not to think of anything in 
particular, and not to fall asleep. Images were pre-processed for resting-state fMRI 
using Statistical Parametric Mapping version 8 (SPM8, 
http://www.fil.ion.ucl.ac.uk/spm/), and in-house Matlab scripts as previously described 
(Serra et al., 2018; Bozzali et al., 2015). Briefly, every participant’s MDEFT was 
segmented in SPM8 in order to obtain probabilistic images of CSF, grey and white 
matter. The grey matter images were used to estimate the participant-specific total GM 
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volume (which was used to adjust the functional connectivity analysis). White matter 
and CSF images were thresholded to compute participant-specific masks of either 
tissue. The mean fMRI signal for both white matter and CSF was extracted using these 
masks. 
In order to assess the functional connectivity between VTA and the rest of the 
brain we followed a pipeline specifically developed for this purpose and previously 
described (Serra et al., 2018). For each participant, the first four volumes of the fMRI 
series were discarded to allow for T1 equilibration effects. The pre-processing steps 
included correction for head motion, compensation for slice-dependent time shifts, and 
normalization to the EPI template in MNI coordinates provided with SPM8. For each 
data set, motion correction was checked to ensure that the maximum absolute shift did 
not exceed 1.5 mm and the maximum absolute rotation did not exceed 1°. Datasets not 
fulfilling these criteria were excluded from further analyses (i.e., 6 patients and 8 
healthy subjects). The signal in every voxel was regressed against the average white 
matter and CSF signals (computed as explained above), as well as against the 6 
realignment parameters. Then, all images were filtered by a phase-insensitive band-pass 
filter (pass band 0.01–0.08 Hz) to reduce the effect of low-frequency drift and high-
frequency physiological noise. We refer to these datasets as unsmoothed corrected data. 
These data were then smoothed via filtering with a 3D Gaussian kernel with 10 mm3 
full width at half maximum. 
2.5. Seed-Based Analyses 
As previously described (Serra et al., 2018), standard space seed masks of the 
left and right VTA were produced by using the Harvard Ascending Arousal Network 
Atlas in MGH152_1mm Space (https://www.martinos.org/) (Edlow et al., 2012) (Figure 
1). A single seed mask was obtained combining left and right regions.  
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Insert Figure 1 around here 
The mean time course within each seed region was extracted (from the 
unsmoothed corrected data) for every participant. The unsmoothed data were chosen for 
this step in order to minimize the partial volume contamination from neighbouring 
nuclei.  The smoothed data were then regressed voxel-wise against these time courses in 
a first-level SPM8 analysis. The resulting beta images were taken to the second level for 
a random-effect group analysis. Finally, at second level, a t-test model was used to 
assess between-group differences (25 DM1 patients vs. 18 HS) in VTA functional 
connectivity. Age and education were used as covariate of no interest.  
Next, we assessed the potential associations between the IGT net-score and 
functional connectivity changes in DM1 patients and HS using a one-sample t-test 
model. Statistical significance was always set at p < 0.05 FWE-corrected at cluster level 
(clusters formed with p<0.001 at voxel level). 
2.6.Data availability statement 
The datasets analyzed during the current study are available from the Corresponding 
Author on request. 
3. Results 
3.1.Demographic, clinical and neuropsychological characteristics 
Patients and controls were not significantly different in age or gender 
distribution (F1,55=0.02, p=0.864; Chi-square=0.08, p=0.78). As expected, there was a 
significant difference between patients and controls in the years of formal education 
(F1,55=59.8, p=0.000) (Table 1). Patients showed normal visuo-spatial logical reasoning 
abilities (mean + SD Raven score: 28.1+6.8; cut-off > 18.9). Conversely, when using 
the social cognition screening battery, 25 out of 31 patients (80.6%) performed below 
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the normality cut-off score on the Story Test (mean + SD score 9.4+2.8; cut-off > 12). 
All these findings replicate and extend previous data (Serra et al., 2016a), thus 
delineating a peculiar neuropsychological profile in DM1 patients.  
3.2.Decision-making performance 
When considering the decks’ choice (Figure 2A) there was a significant Group effect 
(F1,55=5.41, p=0.023) due to the poor performance of DM1 patients. There was also a 
significant Trial effect (F1,168=18.3, p<0.001) due to the more frequent selection of Deck 
B (mean of chosen cards=30.0), followed by Deck D (mean of chosen cards=28.5), 
Deck C (mean of chosen cards=22.7) and Deck A (mean of chosen cards=18.9). There 
was no significant Group by Trial interaction (F1,168=1.7, p=0.15). Both groups 
preferentially selected the disadvantageous Deck B. This is a well-known effect (i.e., 
the prominent Deck B phenomenon) that has been previously described in healthy (Lin, 
Song, Lin & Chiu YC, 2012; Fernie & Tunney, 2006) as well as in pathological 
populations (Ritter, Meador-Woordruff & Dalack, 2004). All individuals are indeed 
insensitive to the long-term outcomes and they demonstrate a short-sightedness in 
situations that involve uncertainty. However, HS, but not DM1 patients, compensated 
the choice of disadvantageous Deck B by selecting more cards from the advantageous 
Decks C and D. When considering the net-score (Figure 2B), a significant Group effect 
(F3,54=4.28; p=0.009) was found, due to the negative net-scores of DM1 patients 
(mean net-score= -1.44) that was significantly different from the positive net-score of 
HS (mean net-score=15.6). The patients’ negative net-score suggests a pathological 
behaviour (i.e., propensity to an immediate high gain regardless of delayed high losses) 
going beyond an attitude to take high-risk choices.  
Insert Figure 2 around here 
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3.3. Resting-state fMRI 
Images from six DM1 patients showed the presence of movement artefacts and were 
for this reason excluded from the image analyses. The RS-fMRI analyses were therefore   
run on 25 DM1 patients and 26 HS. 
DM1 patients compared to HS revealed a significant increase of functional connectivity 
between VTA and the left supramarginal gyrus (BA40) and the left superior temporal 
gyrus (BA41) (Figure 3).  
    Insert Figure 3 around here 
In DM1 patients, there were negative correlations between IGT’s net-scores and VTA-
driven functional connectivity in the bilateral supplementary motor area (BA6) (Figure 
4) and in the right precentral gyrus (BA4). No significant correlations were found in the 
HS group. 
Insert Figure 4 around here 
 
4. Discussion 
The present study shows for the first time the presence of decision-making 
deficits in patients with DM1, and their association with abnormal patterns of VTA-
driven brain connectivity. Brain connectivity was found here to be abnormally increased 
in DM1 patients, specifically between the VTA and brain areas, which are devoted to 
higher-level functions. Increased connectivity within areas of the association cortex has 
been consistently reported in the literature (Serra et al., 2014; Serra et al., 2016a; 
Minnerop et al, 2011; Serra et al., 2016b), and perhaps might represent a peculiar trait 
of this complex disorder. Previously, in DM1, increased patterns of connectivity were 
found in critical areas of the default-mode network (Serra et., al 2014) and in the 
fusiform gyrus (Minnerop et al, 2011), which were associated with or contributed to 
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explain patients’ personality traits (Serra et., al 2014). Similarly, increased patterns of 
network connectivity were identified in association with the severity of patients’ deficits 
in social cognition (i.e., Theory of Mind) (Serra et al., 2016a). All these data support the 
hypothesis that increased brain connectivity may represent the neurobiological substrate 
for the cognitive and behavioural manifestations observed in DM1. As anticipated in the 
introduction section, the exact meaning of increased connectivity remains unclear.  
Indeed, it should be noted that previous fluorodeoxyglucose (FDG)-positron 
emission tomography (PET) have reported patterns of decreased metabolism in DM1 
brains, particularly in frontotemporal areas (Weber et al., 2010; Renard et al., 2016; 
Peric et al., 2017). This is in apparent contrast with our hypothesis. However, the 
relationship between brain metabolism and fMRI connectivity remains largely unclear 
(Savio et al., 2017). Further clarifications might stem from studies using DAT-SPECT 
or Dopa/reclopride-PET in DM1 patients, investigating the relationship between 
neurotransmission, metabolism, and connectivity. It should also be noted that functional 
connectivity measures the correlation between brain activity in segregated brain areas 
(at rest), and not the activity itself. Therefore, it does not necessarily imply increased or 
decreased metabolism. The combination of increased brain connectivity with 
microstructural brain tissue abnormalities (Serra et al., 2015; Minnerop et al., 2011; 
Gliem et al., 2019), that are strictly associated with patients’ genetic loads (Serra et al., 
2015), suggests that, in DM1, complex neurodevelopmental modifications may result in 
complex higher-level dysfunction. Critically, the current study reveals abnormal 
connectivity between VTA and temporo-parietal brain regions. As VTA is rich in 
dopaminergic neurons, it is reasonable to speculate that such abnormalities might be 
driven, at least partially, by a selective subcortical involvement of the dopaminergic 
system. Notably the present findings are consistent with those reported in a recent study 
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based on an animal model of DM1 (i.e., Mbnl2 knockout mouse) (Ramon-Duaso et al., 
2018). Ramon-Duaso and Co-authors reported, in Mbnl2 knockout mice, the occurrence 
of progressive cognitive and affective alterations associated with hyperactivation of the 
dopaminergic system within the prefrontal cortex (Ramon-Duaso et al., 2018). 
Moreover, such a dopaminergic modulation was associated with profound perturbations 
in neural activity and microgliosis, thus suggesting a relationship between dopaminergic 
modulation and microstructural brain tissue modifications. Of course, without evidence 
of dopaminergic dysfunction in our sample, we can only speculate that our findings 
might reflect a similar mechanism. Further studies are needed to clarify the pathology 
underpinning our findings, and therefore their potential relevance for future 
developments in the pharmacological treatment of DM1, not only in a symptomatic 
perspective, but also in terms of potential disease-modifying therapies.  
Nevertheless, it remains to be clarified whether increased functional connectivity 
may be regarded as a measure of hyperfunctioning dopaminergic neurons or may rather 
reflect some compensatory mechanisms consequent to hypofunctioning of the 
dopaminergic system. Future in vivo studies using dopaminergic tracers are mandatory 
to address this issue.   
All DM1 patients recruited here had an adult or childhood-juvenile disease 
onset, and showed a severe impairment of social cognition with sparing of logical 
abilities. When tested using the IGT, DM1 patients showed a substantial impairment in 
their decision-making abilities. Critically, their negative net score on the IGT indicates a 
pathological behaviour in taking high-risk decisions aimed to achieve an immediate 
reward and an instantaneous gratification. This behaviour is an expression of patients’ 
impulsivity and inability to inhibit maladaptive conducts. In real life, this dysfunction in 
decision-making abilities might account for DM1 patients’ difficulties in social and 
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professional interactions, and probably shares some common aspects with their 
personality traits (Serra et al., 2014). 
In terms of neuronal substrate, decision-making is a complex process that 
involves both cortical and subcortical circuits. While the subcortical dopaminergic areas 
respond to reinforced stimuli and induce a prompt reaction for an immediate reward, the 
cortical areas inhibit the instinctual behaviours to obtain more functional long-term 
gains through the activation of the cognitive and impulse control systems. Subcortical 
and cortical abnormalities within this neuronal circuitry have been described in other 
neurological and psychiatric conditions characterized by decision-making deficits 
(Whitton, Treadway & Pizzigalli, 2015; Evens, Hoefler, Biber & Lueken, 2016; 
Deserno, Schlagenhauf, Heinz, 2016). 
From a neuroimaging point of view, we found in DM1 patients, a pattern of 
increased functional connectivity between VTA and the left supramarginal (BA40) and 
superior temporal (BA41) gyri. Interestingly, these areas fall within one of the major 
nodes of the default mode network and, consistently with a previous study (Serra et al., 
2014), it predominantly involves the left hemisphere. It is not clear why the left 
hemisphere appears to be predominantly affected, and further studies are needed to 
confirm this finding. When looking at associations between VTA-driven functional 
connectivity and DM1 patients’ IGT net-scores, a negative correlation was found in the 
supplementary motor area (BA6) of both sides and in the precentral gyrus (BA4). The 
supplementary motor area (BA6) is an association cortex involved in the planning and 
sequencing of voluntary movements (Nachev, Kennard, Husain, 2008), whereas the 
precentral gyrus (BA4) is the primary motor cortex. An activation of BA6 and BA4 was 
previously described in healthy subjects (Lawrence, Jollant, O’Daly, Zelaya & Phillips, 
2009) when performing the IGT in a fMRI study. Lawrence and co-workers concluded 
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that subjects showing a greater sensitivity to uncertainty have more careful planning of 
motor responses, especially during the high-risk trials (Lawrence, Jollant, O’Daly, 
Zelaya & Phillips, 2009). Against this background, we speculate that in DM1 patients a 
VTA-mediated dopaminergic overflow may produce a hyperconnectivity in BA6 and 
BA4, thus reducing patients’ ability to anticipate the reward/punishment and learn a 
winning strategy. Consistent with this hypothesis, it has been previously shown that 
VTA dopaminergic neurons respond to the reward system (Schultz, Dayan, Montague, 
1997; Brocka, et al., 2018) and play a critical role in adaptive decision-making (Richter 
& Gruber, 2018). Additionally, a dopaminergic overdose induced by replacement 
therapy was demonstrated to affect decision-making in patients with Parkinson’s 
disease (Evans, Hoefler, Biber & Lueken, 2016). 
Another point of the present results worth highlighting is that all the brain areas 
we found modulated by VTA connectivity and associated with IGT performance in 
DM1 patients are also part of the mirror neuron system (Rizzolatti & Craighero, 2004). 
The mirror neuron system is implicated in different aspects of social cognition (i.e., 
theory of mind, empathy, etc.) as well as in reward-related brain modulation (Cook, 
Bird, Catmur, Press & Heyes, 2014). Indeed, the neural activation related to reward is 
involved in the selection of the actions driven by a goal-directed behaviour (Cook, Bird, 
Catmur, Press & Heyes, 2014). 
This study suffers from some limitations. First, the sample size was relatively 
small. However, this was by definition an exploratory study and DM1 is a relatively 
rare condition. Despite this limitation, our results were significant (as predicted by our 
power calculation). Second, RS fMRI is known to be potentially affected by motion 
artefacts and other sources of biases. We have addressed this issue by thoroughly 
checking our data and excluding participants with showing evidence of movement. Of 
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note, based upon this criterion we excluded more healthy participants than patients, 
suggesting that the findings cannot be explained by motion. Finally, it should be noted 
that the fMRI signal was regressed against the mean white matter CSF signals, which 
were extracted using the result of automated segmentation. It is possible that the 
presence of white matter lesions, a feature of DM1 (Meola & Cardani, 2015), might 
have affected the results of this segmentation. However, no obvious biases were 
observed after careful examination of the output. In addition, as white matter masks 
were purely used for computing the average signal, we do not expect the effect to be 
significant. 
In conclusion, the current study indicates that a prominent deficit of decision-
making in patients with DM1 might be related with an increased connectivity between 
VTA dopaminergic neurons and brain areas that are critical for the reward/punishment 
system and for social cognition. Given the small sample size, these results should be 
replicated in larger cohorts before generalisation. Nevertheless, these findings support 
the hypothesis that, in DM1, a common neurodevelopmental substrate may affect a set 
of higher-level functions accounting for the daily difficulties experienced by patients. 
To date, the exploration of computational models of dopamine in value-based 
decision making has not been extensively investigated using direct pharmacological 
challenges in human subjects. Undoubtedly, future directions include the need to study 
how dopamine modulation influences the constituent components of value in human 
choice. Nonetheless, some evidence of efficacy of cognitive behavioural therapy on 
clinical symptoms in patients with DM1 has been shown by a single-blind randomised-
trial (Okkersen et al., 2018).  The comprehension of brain connectivity changes 
associated to clinically meaningful symptoms of DM1 might identify potential targets 
20 
 
for neurophysiological modulation, as shown in other neurological disorders (Koch et 
al., 2014; Koch et al., 2018). 
Following the results of the current study, we hypothesize some future direction 
in terms of clinical trials that should be designed to identify appropriate treatments for 
the higher level dysfunctions observed in patients with DM1. First, specific cognitive 
trainings with a focus on decision-making abilities should be developed and tested for 
their potential to improve patients’ dysfunctions and quality of life. Second, in our 
cohort of DM1 patients, we identified a set of cortical regions (i.e., supramarginal gyrus 
[BA40]; superior temporal gyrus [BA41]; supplementary motor area [BA6]; right 
precentral gyrus [BA4]) that might be considered as suitable targets for non-invasive 
brain modulation. Trials using TMS or Transcranial Direct-Current Stimulation (tDCS) 
should therefore be designed (in isolation or in combination with cognitive trainings) to 
test the efficacy of brain modulation in improving patients’ dysfunctions. Finally, this 
work suggests a prominent role for increased VTA connectivity in determining patients’ 
symptoms. Clinical trials should be designed to test the potential efficacy of 
antidopaminergic agents, which are expected to reduce the dopamine outflow. A proven 
efficacy of antidopaminergic drugs would confirm the causative role of VTA in 
determining higher level dysfunctions in DM1 patients, and would open to more 
invasive perspectives of treatment, such as using Deep Brain Stimulation (DBS) in 
selected patients who would not respond to non-invasive interventions. Although the 
mechanism by which DBS produces beneficial effects in neuropsychiatric conditions is 
still not completely understood (Chiken et al., 2016), one could hypothesize DBS 
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Figure 1. Seed area used to assess connectivity in VTA  
The figure illustrates the anatomical point used as seed to assess connectivity starting 
from VTA. For the anatomical definition of VTA the Harvard AAN Atlas was used 
(https://www.martinos.org/) (Edlow et al., 2012). For the purpose of the illustration the 
VTA is overlaid onto the Ch2bet template using mricron 
(http://people.cas.sc.edu/rorden/mricron/). 
Abbreviations: AAN=Ascending Arousal Network; R= Right; VTA= Ventral 
Tegmental Area 
See text for further details. 
Figure 2. Iowa Gambling Task performances 
Panel A: trial-by-trial Iowa Gambling Task performances; panel B: Iowa Gambling 
Task net-scores obtained by patients with DM1 (in yellow) and by healthy subjects (in 
blue). The asterisk indicates significant difference between groups. 
Abbreviations: DM1= Myotonic Dystrophy type 1; HS= Healthy Subjects 
See text for further details. 
 




As shown in the plots, DM1 patients compared to controls exhibited an increase of 
functional connectivity in the left supramarginal gyrus (BA40) and in the left superior 
temporal gyrus (BA41). 
Abbreviations: BA= Brodmann area; DM1= Myotonic Dystrophy type 1; FC= 
Functional Connectivity; HS= Healthy Subjects; L= Left. 
See text for further details. 
 
Figure 4. Associations between VTA-driven Functional Connectivity and Iowa 
Gambling Task performance in DM1 patients. 
Patients showed negative correlations (as shown by the plots) between IGT-net scores 
and functional connectivity in the left supplementary motor area (BA6) and in the right 
precentral gyrus (BA4).  
Abbreviations: BA= Brodmann area; DM1= Myotonic Dystrophy type 1; FC= 
Functional Connectivity; L= Left; R=Right. 




Table 1. Principal demographic and clinical characteristics of studied subjects. 













Gender (F/M) 12/19 11/15 0.782 b 
Mean (SD) years of formal education 12.1 (2.6) 17.5 (2.8) 0.000. a 
Mean (SD) [range] CTG triplets expansion 467 (272) [73-1200] - - 
Mean (SD) [range] MIRS score 2.8 (0.7) [2-4] - - 
a One-way ANOVA; b Chi-square. 
Abbreviations: DM1=Myotonic Dystrophy type-1; MIRS=Muscular Impairment Rating 
Scale; HS=Healthy Subjects, 
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